SUBSCRIBE
SUBSCRIBE
News   Business

ImmunoGen, Inc. Licenses Anti-Cancer Technology to Amgen (JOBS); ImmunoGen to Get Up to $34 Million in Milestone Payments

November 20, 2009 | 
1 min read
Bookmark and Share

Reuters -- Drugmaker ImmunoGen Inc said it licensed its technology to develop anti-cancer drugs to Amgen Inc for a $1 million upfront payment.
Alliances
Amgen
MORE ON THIS TOPIC
Inspect the property. Businessman boss using a magnifying glass to look at piles of money. vector
Insights
JPM26: As Capital Concentrates, VCs Scrutinize Founder Pedigree and CEO Fit in Early Biotech
January 15, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker
Microscope icon. Molecule and communication background. Connected lines with dots.
Opinion
Trump Must Make Biotech Innovation a National Priority
January 14, 2026
 · 
7 min read
 · 
Cyriac Roeding
Corporate headquarters of Novo Nordisk in Denmark
Business
JPM26: Novo Refocuses on Diabetes and Obesity Amid Push To Expand GLP-1 Market
January 14, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Pictured: Eli Lilly's headquarters in Indianapolis
Business
JPM26: Lilly Plots Path to Dominance as Obesity Market Enters a New Era
January 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor